An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients.

Trial Profile

An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Pazopanib (Primary) ; Antineoplastics; Lapatinib
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 11 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2018 Planned End Date changed from 1 Dec 2017 to 31 Mar 2018.
    • 04 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top